...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Biogen looks to FDA for approval of early Alzheimers drug.

Koo wrote: "There you go..."In essence, Sandrock said, the futility analysis had happened too soon." Perhaps if BOM went for a longer stretch, it would have netted better Top-Line results."

Two issues there. 1) Remember BETonMACE skipped its planned futility analysis. Who knows what the outcome would have been if the futility analysis or sample size re-estimation interim analyses had happened as originally planned. Would it have been stopped for futility or allowed to continue? 2) As for longer duration of BETonMACE netting better Top-Line results.....we will need to see the full BETonMACE data to understand whether or not there was a near miss or a total miss. If near miss, then yes perhaps longer duration, or more patients, would have yielded a positive top-line outcome. If total miss, then longer duration probably would not have mattered.

BDAZ

2
Oct 22, 2019 01:52PM
2
Oct 22, 2019 02:04PM
2
Oct 22, 2019 02:33PM
1
Oct 22, 2019 02:46PM
1
Oct 22, 2019 03:36PM
1
Oct 22, 2019 03:57PM
2
Oct 22, 2019 04:07PM
3
Oct 22, 2019 05:15PM
3
Oct 22, 2019 05:29PM
4
Oct 22, 2019 05:54PM
3
Oct 22, 2019 06:32PM
4
Oct 22, 2019 06:37PM
4
Oct 22, 2019 07:23PM
5
Oct 22, 2019 09:34PM
9
Oct 22, 2019 11:59PM
3
Oct 23, 2019 01:53AM
2
Oct 23, 2019 07:17AM
4
Oct 23, 2019 08:02AM
1
Oct 23, 2019 08:19AM
2
Oct 23, 2019 08:50AM
1
Oct 23, 2019 09:23AM
2
Oct 23, 2019 10:44AM
1
Oct 23, 2019 12:40PM
1
Oct 23, 2019 12:41PM
3
Oct 23, 2019 12:49PM
2
Oct 23, 2019 12:59PM
4
Oct 23, 2019 01:03PM
Share
New Message
Please login to post a reply